Wall Street brokerages forecast that Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) will report sales of $720,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Oramed Pharmaceuticals’ earnings. The highest sales estimate is $850,000.00 and the lowest is $600,000.00. Oramed Pharmaceuticals posted sales of $600,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 20%. The business is expected to issue its next quarterly earnings report on Monday, April 22nd.
According to Zacks, analysts expect that Oramed Pharmaceuticals will report full-year sales of $2.93 million for the current year, with estimates ranging from $2.50 million to $3.56 million. For the next financial year, analysts expect that the firm will post sales of $2.60 million, with estimates ranging from $2.40 million to $2.80 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that follow Oramed Pharmaceuticals.
Separately, HC Wainwright set a $25.00 price target on shares of Oramed Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, January 14th.
A hedge fund recently raised its stake in Oramed Pharmaceuticals stock. BlackRock Inc. grew its holdings in shares of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) by 137.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,343 shares of the biotechnology company’s stock after buying an additional 40,114 shares during the quarter. BlackRock Inc. owned approximately 0.40% of Oramed Pharmaceuticals worth $208,000 at the end of the most recent reporting period. 10.50% of the stock is currently owned by hedge funds and other institutional investors.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
Further Reading: What moving averages are used to define a golden cross?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.